Go to main content

NEWS

The latest news
Updates on GC Pharma’s
Journey of supporting
Health and happiness.

소식 상세 테이블 표
Title GC Pharma Reports Full Year 2019 Results
Date of registration 2020-02-12
Attachment File
Contents

All consolidated entities revenues grew plus compare to prior year


YONGIN, South Korea, 12 February 2020 - GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the year ended 31 December 2019.


Key Figures(1)

Full Year 2019(2)

Growth(2)

Total revenues

KRW 1,369.7 billion

+2.6%

Operating profit

KRW 40.3 billion

(19.7%)

K-IFRS profit after taxation

KRW -11.3 billion

-

(1)      Consolidated

(2)      Results and percentages compare to the full financial year 2018


Financial Highlights 

● Delivered total revenue growth of 2.6% KRW 1.37 trillion (2018: KRW 1.33 trillion), all consolidated entities revenues grew plus compare to equivalent 2018 period. 

● Operating profit decreased 19.7% to KRW 40.3 billion (2018: KRW 41.9 billion), primarily due to an impact of investment in R&D and SG&A. 

● One off costs - including corporate tax bill and VAT result in regular tax investigation, evaluation loss of stock investment, impairment losses of tangible asset and penalties from local antitrust regulator related to subsidiary, Green Cross MS, and impairment losses of intangible assets - impacted on after tax profits, expected to progressively ease over the course of 2020.


About GC Pharma

GC Pharma is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in South Korea, GC Pharma is the largest plasma protein product manufacturer in Asia and has been dedicated to quality healthcare solutions more than half a century. Green Cross Corporation updates its corporate brand as GC Pharma in early 2018. Green Cross Corporation remains the company's registered, legal name.


This release includes forward-looking statements, which express the current beliefs and expectations of GC Pharma’s management. Such statements speak only as of the date on which they are made and the company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

 

# # #



List view

이메일집단수집거부

GC녹십자는 이메일 수집을 거부합니다

본 웹사이트에 게시된 이메일 주소가 전자우편 수집 프로그램이나
그 밖의 기술적 장치를 이용하여 무단으로 이메일 주소를 수집하는 행위를 거부하며,
이를 위반시 정보통신망 이용촉진 및 정보보호 등에 관한 법률에 의해 형사처벌됨을
유념하시기 바랍니다

게시일: 2003년 9월 1일